159 related articles for article (PubMed ID: 11964280)
1. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells.
Leimig T; Mann L; Martin Mdel P; Bonten E; Persons D; Knowles J; Allay JA; Cunningham J; Nienhuis AW; Smeyne R; d'Azzo A
Blood; 2002 May; 99(9):3169-78. PubMed ID: 11964280
[TBL] [Abstract][Full Text] [Related]
2. Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter.
Hahn CN; del Pilar Martin M; Zhou XY; Mann LW; d'Azzo A
Proc Natl Acad Sci U S A; 1998 Dec; 95(25):14880-5. PubMed ID: 9843984
[TBL] [Abstract][Full Text] [Related]
3. Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells.
Zhou XY; Morreau H; Rottier R; Davis D; Bonten E; Gillemans N; Wenger D; Grosveld FG; Doherty P; Suzuki K; Grosveld GC; d'Azzo A
Genes Dev; 1995 Nov; 9(21):2623-34. PubMed ID: 7590240
[TBL] [Abstract][Full Text] [Related]
4. Lack of PPCA expression only partially coincides with lysosomal storage in galactosialidosis mice: indirect evidence for spatial requirement of the catalytic rather than the protective function of PPCA.
Rottier RJ; Hahn CN; Mann LW; del Pilar Martin M; Smeyne RJ; Suzuki K; d'Azzo A
Hum Mol Genet; 1998 Oct; 7(11):1787-94. PubMed ID: 9736781
[TBL] [Abstract][Full Text] [Related]
5. Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Model system for revealing the intracellular transport of normal and mutated lysosomal enzymes.
Naganawa Y; Itoh K; Shimmoto M; Kamei S; Takiguchi K; Doi H; Sakuraba H
Biochem J; 1999 Jun; 340 ( Pt 2)(Pt 2):467-74. PubMed ID: 10333491
[TBL] [Abstract][Full Text] [Related]
6. Preclinical dose-finding study with a liver-tropic, recombinant AAV-2/8 vector in the mouse model of galactosialidosis.
Hu H; Gomero E; Bonten E; Gray JT; Allay J; Wu Y; Wu J; Calabrese C; Nienhuis A; d'Azzo A
Mol Ther; 2012 Feb; 20(2):267-74. PubMed ID: 22008912
[TBL] [Abstract][Full Text] [Related]
7. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Bonten EJ; Yogalingam G; Hu H; Gomero E; van de Vlekkert D; d'Azzo A
Biochim Biophys Acta; 2013 Oct; 1832(10):1784-92. PubMed ID: 23770387
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin A/protective protein: an unusual lysosomal multifunctional protein.
Hiraiwa M
Cell Mol Life Sci; 1999 Dec; 56(11-12):894-907. PubMed ID: 11212324
[TBL] [Abstract][Full Text] [Related]
9. Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice.
de Geest N; Bonten E; Mann L; de Sousa-Hitzler J; Hahn C; d'Azzo A
Hum Mol Genet; 2002 Jun; 11(12):1455-64. PubMed ID: 12023988
[TBL] [Abstract][Full Text] [Related]
10. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis.
Bonten EJ; Wang D; Toy JN; Mann L; Mignardot A; Yogalingam G; D'Azzo A
FASEB J; 2004 Jun; 18(9):971-3. PubMed ID: 15084520
[TBL] [Abstract][Full Text] [Related]
11. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo.
Persons DA; Allay JA; Allay ER; Smeyne RJ; Ashmun RA; Sorrentino BP; Nienhuis AW
Blood; 1997 Sep; 90(5):1777-86. PubMed ID: 9292510
[TBL] [Abstract][Full Text] [Related]
12. Identification of the promoters for the human and murine protective protein/cathepsin A genes.
Rottier RJ; D'Azzo A
DNA Cell Biol; 1997 May; 16(5):599-610. PubMed ID: 9174165
[TBL] [Abstract][Full Text] [Related]
13. The atomic model of the human protective protein/cathepsin A suggests a structural basis for galactosialidosis.
Rudenko G; Bonten E; Hol WG; d'Azzo A
Proc Natl Acad Sci U S A; 1998 Jan; 95(2):621-5. PubMed ID: 9435242
[TBL] [Abstract][Full Text] [Related]
14. Transplanted ER-MP12hi20-58med/hi myeloid progenitors produce resident macrophages from marrow that are therapeutic for lysosomal storage disease.
Soper BW; Duffy TM; Lessard MD; Jude CD; Schuldt AJ; Vogler CA; Levy B; Barker JE
Blood Cells Mol Dis; 2004; 32(1):199-213. PubMed ID: 14757436
[TBL] [Abstract][Full Text] [Related]
15. Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
Cadaoas J; Hu H; Boyle G; Gomero E; Mosca R; Jayashankar K; Machado M; Cullen S; Guzman B; van de Vlekkert D; Annunziata I; Vellard M; Kakkis E; Koppaka V; d'Azzo A
Mol Ther Methods Clin Dev; 2021 Mar; 20():191-203. PubMed ID: 33426146
[TBL] [Abstract][Full Text] [Related]
16. New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor.
Malvagia S; Morrone A; Caciotti A; Bardelli T; d'Azzo A; Ancora G; Zammarchi E; Donati MA
Mol Genet Metab; 2004 May; 82(1):48-55. PubMed ID: 15110321
[TBL] [Abstract][Full Text] [Related]
17. Neogenesis of cerebellar Purkinje neurons from gene-marked bone marrow cells in vivo.
Priller J; Persons DA; Klett FF; Kempermann G; Kreutzberg GW; Dirnagl U
J Cell Biol; 2001 Nov; 155(5):733-8. PubMed ID: 11724815
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells.
Matzner U; Schestag F; Hartmann D; Lüllmann-Rauch R; D'Hooge R; De Deyn PP; Gieselmann V
Hum Gene Ther; 2001 Jun; 12(9):1021-33. PubMed ID: 11399225
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional study of K453E mutant protective protein/cathepsin A causing the late infantile form of galactosialidosis.
Takiguchi K; Itoh K; Shimmoto M; Ozand PT; Doi H; Sakuraba H
J Hum Genet; 2000; 45(4):200-6. PubMed ID: 10944848
[TBL] [Abstract][Full Text] [Related]
20. Introduction of the green fluorescent protein gene into hematopoietic stem cells results in prolonged discrepancy of in vivo transduction levels between bone marrow progenitors and peripheral blood cells in nonhuman primates.
Hanazono Y; Terao K; Shibata H; Nagashima T; Ageyama N; Asano T; Ueda Y; Kato I; Kume A; Hasegawa M; Ozawa K
J Gene Med; 2002; 4(5):470-7. PubMed ID: 12221639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
